PROTACs
PROTAC (PROteolysis-TArgeting Chimera) is a heterobifunctional nanomolecule containing two different ligands, ligand for ubiquitin E3 and ligand for target protein. The two parts are connected by linker to form a "three-unit" polymer, target protein ligand-linker-E3 ligase ligand. Building blocks of PROTAC molecules include PROTAC Linker, Ligand for Target Protein for PROTAC, Ligand for E3 Ligase, E3 Ligase Ligand-Linker Conjugate, Target Protein Ligand-Linker Conjugate, etc.
PROTACs Isoform Specific Products
-
PROTACs Related Products (1386)
Related Products (1386)
-
Antibodies (1)
-
PROTACs Isoform Comparison
-
PROTAC SMARCA2 degrader-32
0 ImagesCat. No.: HY-170343CAS No.: 3033586-50-1PROTAC SMARCA2 degrader-32 is a potent, selective SMARCA2 PROTAC degrader, with DC50 values of 1.3 nM and 94 nM against SMARCA2 and SMARCA4, respectively. PROTAC SMARCA2 degrader-32 exhibits IC50 against SMARCA2, SMARCA4 and the VHL E3 ubiquitin ligase of 30 nM, 63 nM and 25 nM, respectively. PROTAC SMARCA2 degrader-32 inhibits the growth of SMARCA4-deficient cancer cells. It can be used in research on cancers such as fibrosarcoma.
-
PROTAC ALK degrader-5
0 ImagesCat. No.: HY-180956CAS No.: 2379672-57-6PROTAC ALK degrader-5 (Compound 17) is an efficient ALK PROTAC degrader, with its inhibitory effects on EML4-ALK and NPM-ALK being 27.4 nM and 116.5 nM respectively. PROTAC ALK degrader-5 exhibits potent anti-proliferative activity against H3122 and Karpas 299. PROTAC ALK degrader-5 effectively inhibits the phosphorylation of ALK and STAT3. PROTAC ALK degrader-5 can be used for the study of ALK-driven malignant tumors, such as human non-small cell lung cancer and anaplastic large cell lymphoma.
-
PROTAC BTK Degrader-12
0 ImagesCat. No.: HY-170413CAS No.: 2736508-65-7PROTAC BTK Degrader-12 is a BTK PROTAC degrader that recruits CRBN, with a DC50 of 0.72 nM. PROTAC BTK Degrader-12 achieves ubiquitin-proteasome pathway degradation of BTK by conjugating a BTK inhibitor domain with an E3 ubiquitin ligase ligand domain. PROTAC BTK Degrader-12 can be used in cancer research.
-
PROTAC FAK degrader 2
0 ImagesCat. No.: HY-163709PROTAC FAK degrader 2 is an orally active PROTAC FAK degrader with a DC50 of 60.10 nM. PROTAC FAK degrader 2 forms a ternary complex with FAK and CRBN E3 ubiquitin ligase, driving proteasome-mediated degradation of total and phosphorylated FAK. PROTAC FAK degrader 2 inhibits phosphorylation of AKT and ERK, suppressing their downstream signaling pathways. PROTAC FAK degrader 2 reduces cancer cell viability, adhesion, migration, and invasion. PROTAC FAK degrader 2 exerts anti-tumor activity in HCT8/T tumor xenografts in mice. PROTAC FAK degrader 2 can be used for the research of breast cancer, colorectal cancer, lung cancer.
-
P19P
0 ImagesCat. No.: HY-180977CAS No.: 2512843-74-0P19P is a BCR-ABL PROTAC degrader based on Ponatinib (HY-12047), with a DC50 value of approximately 20 nM for the wild-type BCR-ABL protein. P19P can effectively degrade various drug-resistant mutants such as T315I, E255K, H396R, and V468F, and exhibits potent anti-proliferative activity in BaF3-BCR-ABL (T315I) cells. P19P maintains strong inhibitory activity against ABL (T315I), with a IC50 of 13.1 nM. P19P does not inhibit the formation of vascular lumens in HUVEC. P19P can be used for research on chronic myeloid leukemia and acute lymphoblastic leukemia.
-
PROTAC CG167
0 ImagesCat. No.: HY-173009PROTAC CG167 is a selective bifunctional PROTAC degrader targeting CypA, with a DC50 of 123 nM. PROTAC CG167 drives ubiquitin-dependent and ubiquitin-like modification-dependent proteasomal degradation of CypA by recruiting the VHL E3 ligase complex. PROTAC CG167 exhibits anti-HIV‑1 and anti-HCV replication activities, and selectively reduces CypA levels in various cells. PROTAC CG167 can be used in studies related to viral infections.
-
SIAIS100
0 ImagesCat. No.: HY-152036CAS No.: 3033463-06-5SIAIS100 is a potent BCR-ABL PROTAC degrader with an DC50 value of 2.7 nM. SIAIS100 can be used to research chronic myeloid leukemia (CML).
-
MS9117
0 ImagesCat. No.: HY-184097CAS No.: 3098670-37-9MS9117 is a PROTAC molecule that targets and degrades LSD1/BHC110 by recruiting CRBN. MS9117 effectively increases the level of histone H3 lysine 4 monomethylation. MS9117 significantly inhibits the proliferation and colony formation of cancer cells, promotes their myeloid differentiation, and enhances the sensitivity of non-acute promyelocytic leukemia-type AML cells to all-trans retinoic acid (ATRA).
-
PROTAC STAT6 degrader-10
0 ImagesCat. No.: HY-183847CAS No.: 3077464-23-1PROTAC STAT6 degrader-10 is a bifunctional STAT6 degrader with a DC50 value of >1 μM. PROTAC STAT6 degrader-10 recruits STAT6 protein to E3 ubiquitin ligase for ubiquitination and subsequent degradation. PROTAC STAT6 degrader-10 can be used for the research of inflammatory disorders, allergies, asthma, eczema.
-
KTX-497
0 ImagesCat. No.: HY-148276CAS No.: 2432993-46-7
-
JY-21
0 ImagesCat. No.: HY-174975JY-21 is a BRD4 PROTAC degrader active against both long and short BRD4 isoforms. JY-21 binds to TRIM28, RACK1, LMO7 and FUS to induce proteasomal degradation of BRD4 isoforms (DC50: 5.944 μM for long BRD4 isoform; 3.797 μM for short BRD4 isoform). JY-21 is applicable to research related to triple-negative breast cancer.
-
d9A1-2
0 ImagesCat. No.: HY-183892CAS No.: 2690350-15-1d9A1-2 is a potent SLC9A1 PROTAC degrader. d9A1-2 binds to SLC9A1 via the d9A1 warhead, recruits the CRL4CRBN E3 ubiquitin ligase through EBM, and thereby induces ubiquitination and proteasomal degradation of SLC9A1. d9A1-2 can be used for research on cancers such as acute myeloid leukemia.
-
UNC8461
0 ImagesCat. No.: HY-183100UNC8461 is a PROTAC and is negative control CRBN-recruiting PROTAC analog of UNC8209 (HY-183098). UNC8461 features a methyl group substitution on its CRBN ligand to disrupt CRBN binding. UNC8461 fails to reduce TBK1, AAK1, GAK, and AURKA protein levels in renal cancer cells. UNC8461 does not suppress 3-D soft agar colony formation in renal cancer cells, and exerts modest, partial inhibition on colony formation in some renal cancer cells.
-
P-SETDB1-4
0 ImagesCat. No.: HY-184362P-SETDB1-4 is a SETDB1 PROTAC degrader with a Kd of 86 nM. P-SETDB1-4 recruits CRBN to SETDB1, induces proteasome-dependent degradation of SETDB1, and forms a ternary complex with CRBN to achieve targeted degradation. P-SETDB1-4 reduces DNA synthesis. P-SETDB1-4 exhibits anticancer activity against breast cancer. P-SETDB1-4 can be used in breast cancer-related research.
-
ZX703
0 ImagesCat. No.: HY-157788ZX703 is a GPX4 PROTAC degrader with a DC50 of 0.135 μM. ZX703 degrades GPX4 via the ubiquitin-proteasome and autophagy-lysosome pathways. ZX703 induces the accumulation of ROS, thereby triggering Ferroptosis. ZX703 can be used in studies related to fibrosarcoma and prostate cancer.
-
KTX-955
0 ImagesCat. No.: HY-148275CAS No.: 2573302-50-6
-
PROTAC c-Met degrader-2
0 ImagesCat. No.: HY-170335CAS No.: 2254608-80-3PROTAC c-Met degrader-2 (PROTAC2) is a PROTAC-based c-Met degrader, with a DC50 of 50 nM.
